GeneSoft Factive Label Should Discourage Prolonged Use, FDA Cmte. Says

GeneSoft's Factive (gemifloxacin) labeling should recommend against exceeding the initial five- or seven-day course of treatment for acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia, members of FDA's Anti-Infective Drugs Advisory Committee said March 4